Anti-A4/ APP/ AAA monoclonal antibody
Anti-A4/ APP/ AAA antibody for FACS & in-vivo assay
Go to APP/APP products collection >>
(antibodies, antigen, VLP, mRNA, ORF viral vector, etc)
Product information
Catalog No. | Product Name | Species Reactivity |
---|---|---|
GM-Tg-hg-T87024-Ab-1/ GM-Tg-hg-T87024-Ab-2 | Anti-Human APP monoclonal antibody | Human |
GM-Tg-rg-T87024-Ab-1/ GM-Tg-rg-T87024-Ab-2 | Anti-Rat APP monoclonal antibody | Rat |
GM-Tg-mg-T87024-Ab-1/ GM-Tg-mg-T87024-Ab-2 | Anti-Mouse APP monoclonal antibody | Mouse |
GM-Tg-cynog-T87024-Ab-1/ GM-Tg-cynog-T87024-Ab-2 | Anti-Cynomolgus/ Rhesus macaque APP monoclonal antibody | Cynomolgus/ Rhesus macaque |
GM-Tg-felg-T87024-Ab-1/ GM-Tg-felg-T87024-Ab-2 | Anti-Feline APP monoclonal antibody | Feline |
GM-Tg-cang-T87024-Ab-1/ GM-Tg-cang-T87024-Ab-2 | Anti-Canine APP monoclonal antibody | Canine |
GM-Tg-bovg-T87024-Ab-1/ GM-Tg-bovg-T87024-Ab-2 | Anti-Bovine APP monoclonal antibody | Bovine |
GM-Tg-equg-T87024-Ab-1/ GM-Tg-equg-T87024-Ab-2 | Anti-Equine APP monoclonal antibody | Equine |
Size: 1mg | 10mg | 100mg
Product Description
Catalog No. | GM-Tg-hg-T87024-Ab-1/ GM-Tg-hg-T87024-Ab-2; GM-Tg-rg-T87024-Ab-1/ GM-Tg-rg-T87024-Ab-2; GM-Tg-mg-T87024-Ab-1/ GM-Tg-mg-T87024-Ab-2; GM-Tg-cynog-T87024-Ab-1/ GM-Tg-cynog-T87024-Ab-2; GM-Tg-felg-T87024-Ab-1/ GM-Tg-felg-T87024-Ab-2; GM-Tg-cang-T87024-Ab-1/ GM-Tg-cang-T87024-Ab-2; GM-Tg-bovg-T87024-Ab-1/ GM-Tg-bovg-T87024-Ab-2; GM-Tg-equg-T87024-Ab-1/ GM-Tg-equg-T87024-Ab-2 |
Products Name | Anti-APP monoclonal antibody |
Format | mab |
Target Name | APP |
Protein Sub-location | Transmembrane Protein |
Category of antibody | FACS/Biofunctional Antibody, Therapeutics Target antibody |
Derivation (species) | Mouse |
CH1+2+3 Isotype (Receptor identification) | IgG |
Type of Light Chain (VD-LC) | N/A |
Expression platform | Mammalian Expression |
Bioactivity validation | Binding affinity is validated by using flow cytometry with antigen overexpressed cell line. The biofunction of antibodies are validated in cell-based assay (IC50 or EC50 TBD). |
Tag | Fc |
Products description | Pre-made anti-APP benchmark inhibitory monoclonal antibody(mab) (blocking antibody inhibitor) is expressed by mammalian cell line as a benchmark antibody for cell culture, FACS,ELISA or other affinity binding assay or functional assay development, animal model development, PK/PD model development (Pharmacokinetics & Pharmacodynamic) |
Purity | Purity: ≥95% (SDS-PAGE) |
Application | Biological drug disovery including cell culture, assay development, animal model development, PK/PD model development (Pharmacokinetics & Pharmacodynamic) and mechanism of action (MOA) research. |
Formulation | Lyophilized from sterile PBS, PH 7.4 |
Storage | Store at -20℃ to -80℃ under sterile conditions. Avoid repeated freeze-thaw cycles. |
Reference
Data / case study
Click to get more Data / Case study about the product.
Associated products
Target information
Target ID | GM-T87024 |
Target Name | APP |
Gene ID | 351,11820,54226,100427716,403407,101085564,280722,100066294 |
Gene Symbol and Synonyms | AAA,ABETA,ABPP,AD1,Adap,Ag,alpha-sAPP,APP,APPI,betaApp,CTFgamma,CVAP,E030013M08Rik,PN-II,PN2,preA4 |
Uniprot Accession | P05067,P08592,P29216,Q28280,P86906,Q28053 |
Uniprot Entry Name | A4_HUMAN,A4_MACMU,A4_RAT,A4_FELCA,A4_CANLF,A4_BOVIN |
Protein Sub-location | Transmembrane Protein |
Category | Therapeutics Target, INN Index |
Disease | N/A |
Gene Ensembl | ENSG00000142192 |
Target Classification | N/A |
The target: APP, gene name: APP, also named as AAA, ABETA, ABPP, AD1I, CTFgamma, CVAP, PN-II, PN2, preA4, APP. This gene encodes a cell surface receptor and transmembrane precursor protein that is cleaved by secretases to form a number of peptides. Some of these peptides are secreted and can bind to the acetyltransferase complex APBB1/TIP60 to promote transcriptional activation, while others form the protein basis of the amyloid plaques found in the brains of patients with Alzheimer disease. In addition, two of the peptides are antimicrobial peptides, having been shown to have bacteriocidal and antifungal activities. Mutations in this gene have been implicated in autosomal dominant Alzheimer disease and cerebroarterial amyloidosis (cerebral amyloid angiopathy). Multiple transcript variants encoding several different isoforms have been found for this gene. [provided by RefSeq, Aug 2014].
About Gmab
GMab, developed by GeneMedi, constitutes an advanced library of recombinant monoclonal antibodies, each meticulously designed to target specific molecular entities. Leveraging the sophisticated capabilities of GM’s Taurus™ and LIBRA™ platforms, GMab synthesizes antibodies characterized by high binding affinity, exceptional physicochemical stability, and optimal developability profiles.
Through expression in mammalian cell lines, GMab has been established as a paradigmatic reference antibody. It holds significance in myriad domains of biological drug discovery, encompassing cellular cultivation, innovative assay methodologies, strategic animal model systematization, in-depth pharmacokinetic & pharmacodynamic (PK/PD) modeling, and intricate mechanism of action (MOA) investigations.